Insider Trading Stories
Disposition of 215600 shares by Johnson John of Xeris Pharmaceuticals at 1.99 subject to Rule 16b 3
just now at MacroaxisInsider Filed By Johnson John, Xeris Pharmaceuticals |
Filed transaction by Xeris Pharmaceuticals Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e). Disposition of 215600 stock option (right to buy) at 1.99 of Xeris Pharmaceuticals by Johnson John on 18th of March 2024. This event was filed by Xeris Pharmaceuticals with SEC on 2024-03-18. Statement of changes in beneficial ownership - SEC Form 4 [Continue Reading...]
- XERS Xeris Pharmaceuticals
- Latest Acquisition by John Schmid of 4500 shares of Xeris Pharmaceuticals at 2.16 subject to Rule 16b-3
- XERS 2.13 -0.1
- Low 2.11
- High 2.25
- Volume 1.5 M
- Alpha 0.0684
- Beta 2.13
- Return On Equity -3.24
- Return On Asset -0.0825
- Profit Margin (0.38) %
- Operating Margin (0.22) %
- Current Valuation 469.95 M
- Shares Outstanding 140.45 M
- Shares Owned By Insiders 3.72 %
- Shares Owned By Institutions 44.80 %
- Number Of Shares Shorted 9.64 M
- Price To Book 3.86 X
- Price To Sales 1.91 X
- Revenue 163.91 M
- Gross Profit 87.61 M
- EBITDA (30.85 M)
- Net Income (62.26 M)
- Cash And Equivalents 111.55 M
- Cash Per Share 0.82 X
- Total Debt 229.19 M
- Debt To Equity 1.87 %
- Current Ratio 2.50 X
- Book Value Per Share (0.05) X
- Cash Flow From Operations (48.21 M)
- Short Ratio 5.05 X
- Earnings Per Share (0.45) X
- Target Price 4.7
- Number Of Employees 377
- Beta 1.21
- Market Capitalization 313.21 M
- Total Asset 322.6 M
- Retained Earnings (617.02 M)
- Working Capital 61.07 M
- Z Score -1.44
- Net Asset 322.6 M
- Accumulation Distribution 91423.36
- Daily Balance Of Power (0.71)
- Rate Of Daily Change 0.96
- Day Median Price 2.18
- Day Typical Price 2.16
- Price Action Indicator (0.10)
- Period Momentum Indicator (0.10)
Filed transaction by Viant Technology Officer: Chief Financial Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e). Disposition of 61229 class a common stock at 10.13 of Viant Technology by Madden Larry on 10th of March 2024. This event was filed by Viant Technology with SEC on 2024-03-10. Statement of changes in beneficial ownership - SEC Form 4 |
just now at Macroaxis Filed for Madden Larry |
Filed transaction by Signing Day Sports Officer: Vp Of Hr And Secretary. Grant, award or other acquisition pursuant to Rule 16b-3(d). Signing insider trading alert for acquisition of common stock by Trent Whitehead, Officer: Vp Of Hr And Secretary, on 12th of March 2024. This event was filed by Signing Day Sports with SEC on 2024-03-12. Statement of changes in beneficial ownership - SEC Form 4 |
just now at Macroaxis Filed for Trent Whitehead |
Filed transaction by Signing Day Sports Officer: Vp Of Hr And Secretary. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e). Disposition of 10000 employee stock option (right to buy) at 2.5 of Signing Day by Trent Whitehead on 4th of March 2024. This event was filed by Signing Day Sports with SEC on 2024-03-04. Initial filing of beneficial ownership - SEC Form 3 |
just now at Macroaxis Filed for Trent Whitehead |
Filed transaction by Signing Day Sports Director. Grant, award or other acquisition pursuant to Rule 16b-3(d). Signing insider trading alert for acquisition of common stock by Borish Peter F, Director, on 1st of March 2024. This event was filed by Signing Day Sports with SEC on 2024-03-01. Statement of changes in beneficial ownership - SEC Form 4 |
just now at Macroaxis Filed for Borish Peter F |
Filed transaction by Avidity BiosciencesInc Director, Officer: President And Ceo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e). Disposition of 84000 common stock at 21.3894 of Avidity BiosciencesInc by Sarah Boyce on 8th of March 2024. This event was filed by Avidity BiosciencesInc with SEC on 2024-03-08. Statement of changes in beneficial ownership - SEC Form 4 |
just now at Macroaxis Filed for Sarah Boyce |
Filed transaction by Avita Medical Officer: Cfo. Grant, award or other acquisition pursuant to Rule 16b-3(d). Acquisition of 1000 common stock at 17.38 of Avita Medical by O'toole David D on 28th of February 2024. This event was filed by Avita Medical with SEC on 2024-02-28. Statement of changes in beneficial ownership - SEC Form 4 |
just now at Macroaxis Filed for O'toole David D |
Filed transaction by IGM Biosciences Officer: Chief Business Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e). Disposition of 1798 common stock at 9.8752 of IGM Biosciences by Lisa Decker on 13th of March 2024. This event was filed by IGM Biosciences with SEC on 2024-03-13. Statement of changes in beneficial ownership - SEC Form 4 |
just now at Macroaxis Filed for Lisa Decker |
Filed transaction by IGM Biosciences Director, 10 Percent Owner: . Grant, award or other acquisition pursuant to Rule 16b-3(d). Acquisition of 29400 non- qualified stock option (right to buy)uy) at 9.95 of IGM Biosciences by Baker Bros. Advisors Lp on 12th of March 2024. This event was filed by IGM Biosciences with SEC on 2024-03-12. Statement of changes in beneficial ownership - SEC Form 4 |
just now at Macroaxis Filed for Baker Bros. Advisors Lp |
Filed transaction by IGM Biosciences Director, 10 Percent Owner: . Grant, award or other acquisition pursuant to Rule 16b-3(d). IGM insider trading alert for acquisition of common stock by Redmile Group, Llc, Director, 10 Percent Owner: , on 28th of February 2024. This event was filed by IGM Biosciences with SEC on 2024-02-28. Statement of changes in beneficial ownership - SEC Form 4 |
just now at Macroaxis Filed for Redmile Group, Llc |